NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

NCT01480674

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Interventions: Trastuzumab

Countries: France

This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without progression for at least three years. Patients will be followed prospectively for one year.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Female patients, \>/= 18 years of age
* HER2-positive metastatic breast cancer or locally advanced breast cancer
* Systemic treatment included Herceptin as 1st line therapy
* Without progression for at least 3 years after the beginning of Herceptin treatment
* Alive or not alive and treated or not treated with Herceptin at the time of inclusion

Exclusion Criteria:

* Disease progression \<3 years after beginning 1st-line therapy with Herceptin

Locations (78)

Agen, France
Aix-en-Provence, France
Aix-en-Provence, France
Ajaccio, France
Amiens, France
Amiens, France
Arras, France
Aubervilliers, France
Auxerre, France
Béziers, France
Bordeaux, France
Bordeaux, France
Bourg-en-Bresse, France
Brest, France
Brive-la-Gaillarde, France
Caen, France
Carcassonne, France
Carcassonne, France
Chalon-sur-Saône, France
Clermont-Ferrand, France
Clermont-Ferrand, France
Dax, France
Dechy, France
Dijon, France
Guilherand-Granges, France
Hyères, France
La Chaussée-Saint-Victor, France
La Roche-sur-Yon, France
La Tronche, France
Lille, France
+ 48 more on CT.gov